← board
ARTL
distress 7/10 · high distress / dilution risk$1.05-2%today-99% from 52w high
Revenue
pre-revenue
Liquidity
$10M
Runway
1.5 yrs
Shares 1y
+77%
Price & events
-79.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
-7.9%
1W
-16.7%
1M
-73.7%
3M
-79.8%
6M
-97.6%
1Y
-95.8%
2Y
-99.6%
5Y
-99.5%
All
Overview
- Market Cap
- $2.45M
- Volume
- 7.49K
- 52 Week Range
- $1.00 – $71.63
- Total Shares
- 2.33M
- Float Shares
- 2.17M
- Short %
- 5.62%
- % Held by Insiders
- 2.47%
- % Held by Institutions
- 8.10%
- RVOL
- 0.03x
- Beta
- -0.11
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2026-03-30partnershipClosed private placement of shares and warrants, raising $10 million net proceeds.SEC 8-K
- 2026-02-02fda agreementNasdaq granted exception to cure listing deficiencies, must demonstrate compliance by March 30, 2026.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-11-19Maxim GroupBuy → Hold
- 2025-09-08D. Boral CapitalBuy → Hold
- 2025-08-26D. Boral CapitalBuy
- 2025-08-18D. Boral CapitalBuy
- 2025-08-06D. Boral CapitalBuy
- 2025-08-04D. Boral CapitalBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.